Mikhail Blagosklonny’s Plan for Oncology

Mikhail Blagosklonny is a researcher, professor, writer, and philanthropist. He is a graduate of the First Palov State Medical Uniersity of Saint Petersburg with an M.D. in Internal Medicine as well as a PhD in Experimental Medicine and Cardiology. He was a Professor of Medicine in New York Medical College until 2002. He is currently based in Roswell Park Cancer Institute as a professor of Oncology since 2009. Before this, he was a senior scientist at Ordway Research Institute in Albany, New York. He is an editor at Oncotarget, a journal of oncology, where he is specifically responsible for articles related to cell death and differentiation. Blagosklonny has written more than 300 publications to this day and learn more about Mikhail.

Blagosklonny’s passion is the research of cell aging and death and their connection to cancer. Blagosklonny’s goal is to find cancer treatment, which is affordable and easy on the body, unlike modern chemotherapy which is extremely tough for cancer patients to live through and recover from. Finding a medicine, which kills only the cancer cells is a way to reduce the damage to the whole body, as is the case with chemotherapy and read full article.

The main pathway through this is stopping cells from aging and dying. His advancement to this is the discovery of the rapamycin molecule’s effect on the cell cycle. Rapamycin helps stop the cellular pathway of the body from producing cells which cause aging. These aging cells make the cells of the body grow and divide, which ages them. Rapamycin lowers these processes for cancer cells as well which is handling one of the main problems of cancer patients – the rapid growth and division of cancer cells. It works by inhibiting MTOR signaling and stopping cellular senescence. MTOR pathway is activated by hormones, nutrients, growth triggers and oxygen. It thus slows the aging process and extends life span and Mikhail lacrosse camp.

According to him, aging is a systematic hyperfunction of the growth process. Aging is a continuation of cell growth which proves that it is not really a natural program to the body, since growth of the organism should cease when the body reaches its maximum size. Rapamycin stops this program and in this way prevents the threat of possible cancer formations. In the case of an existing cancer formation, rapamycin stops the already began process of cell division and overgrowth. Blagosklonny hopes that, through his findings, future scientists will be able to develop anti-aging medicines, eliminate cancer forever, and maybe even prolong life and more information click here.

More Visit: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531/

Meet the Titan of Cosmetic Surgery-Dr. Jennifer Walden

Our physical appearance is very sensitive and not something we are ready to risk. Despite the medical progress that has led to the introduction of cosmetic surgery, many people are a little hesitant to give it a shot. This is because they have been many operations that they have seen gone wrong. It is this fear that has led people living trying to cover up for a body part they don’t like, all their life. The mistake people make is visiting uncertified doctors for such services.

The Austin residents are lucky to have Dr Walden. She is a cosmetic surgeon who is certified by the American Board of Plastic surgery. Surviving in this field has been through great determination. This is because this is considered a field for men. This means she must ensure that her clients trust her. Her eight years of experience has helped her do most of this part.

Dr Walden says that 91% of the cosmetic surgery patients are women. Most of them feel comfortable discussing their medical advice with the female surgeons. This is because there is a mutual understanding and hence no judgments. She says that she understands the body changes that occur after giving birth. She also feels the body changes, being a mother of seventeen old months’ twins.

Dr Walden is committed to ensuring that her patients leave with their expectations exceeded. It is the passion that she has to empower fellow women that keep her going .Dr. Walden says that her obligation is to produce better people from her patients. If this didn’t happen, she would just close down her business.

Dr Walden encourages women to drop their fear and continue showing up for surgery. She goes further to give an example of her home friend, who was in need of breast surgery. It was after a long time that she gave it a try. She is now happy and confident with her new look. Why wait any longer? Just do it and live your dream

 

The Biopharmaceutical Giant: Amicus Therapeutics

Amicus Therapeutics is a Biopharmaceutical Company founded on February 2nd, 2002.The biotechnological company is located in Cranbury New Jersey in the United States. Amicus Therapeutics became a publicly owned company in 2007 withdrawing from its funding by Canaan Partners, Radius Ventures and New Enterprise Associates. The primary focus of Amicus Therapeutics is the provision of therapies and treatments for orphan and common diseases which come in the form of unique genetic disorders among other forms. These rare diseases are collectively called lysosomal storage disorders.

 

John F. Crowley is the CEO OF Amicus Therapeutics having succeeded Donald Hayden in 2010.Since then Hayden remained a close associate of Amicus Therapeutics (WeeklyOpinion). Other important stakeholders of the company are Bradley L. Campbell and William D. Baird 111 as chief financial officer. In the year 2014 Amicus Therapeutics became recognized worldwide for having the most extensive portfolio of pharmacological chaperones that are small.

 

Amicus Therapeutics widely bases the development of its products on the Chaperone-Advanced Replacement Therapy (https://www.crunchbase.com/organization/amicus-therapeutics). Migalastat is Amicus Therapeutics’ most advanced pharmacological chaperone that is used in the treatment of Fabry disease. Migalastat in the treatment of Fabry disease is used concerning the special and unique genetic diagnosis. In a bid to help in the overall management of lysosomal diseases Amicus Therapeutics is in the advanced stages of developing a therapy for Epidermylosis Bullosa which is a connective tissue disorder.

 

In partnership with JCR Pharmaceutical and GlaxoSmithKline for the past three years Amicus Therapeutics, have been working to investigate further on the causes and effects of lysosomal storage disorders. As far as collaborations are concerned, Amicus Therapeutics has had its share of failures, for example, the untimely cancellation of its collaboration with The Shire. This cancellation of partnership led to the opening of the company as a public company due to financial strains. Amicus Therapeutics relies on manufacturing contracts as it does not have its manufacturing plants.

 

Over the years the company has grown despite setbacks related to partnerships. It has expanded its research site to San Diego. Amicus Therapeutics took over ownership of one of its main competitors the Callidus Biopharma.